A PROSPECTIVE STUDY ON HEMOVIGILANCE AND BLOOD TRANSFUSION SAFETY PRACTICES – IMPACT OF CLINICAL PHARMACIST.

Authors

  • Mekkanti Manasa Rekha Pharm.D, RCPh, (Ph.D) ,FSASS, Assistant Professor, Scientist, Department of Pharmacy Practice, Gautham College of Pharmacy Bangalore , Karnataka, India and Research Scholar in Department of Pharmacy Practice, M.S. Ramaiah University of Applied Sciences Bangalore, Karnataka, India

DOI:

https://doi.org/10.37591/tdd.v9i3.1228

Keywords:

Adverse Transfusion Reaction, Blood transfusion, Packed Red Blood Cells, Delayed Hemolytic Transfusion Reactions, Anaphylactic.

Abstract

AIM & BACKGROUND:Blood Transfusions are lifesaving intervention but are associated with
potential to cause adverse events. The present study is conducted to track ATR’s patterns associated with
blood and blood products and generate evidence-based recommendations and to promote optimal blood
usage.
METHODS & MATERIALS: The present study is a prospective, observational and interventional study
conducted over a period of 10 months at ESI hospital, Indiranagar. About 90 patients undergoing
transfusions were selected for the study. Forms, Case sheets, Treatment charts were used to collect the
data. Descriptive statistics & Prism graph software was used to analyse the data collected.
RESULTS:Among the 90 participants in the study51 (56.66%) were found to be females and 39
(43.33%) were males. Patients in this age range made up the most people overall.30-40 accounting for
28.8% (26) followed by the least no of patients were in the 20-30 and 70-80(7.7%) age group
respectively. Majority of Indications for blood transfusion was made for Anaemia accounting for 47.7%
(43). Whereas minimum indication was made for cardiac related cases accounting for 2 (2%). A total of
208 transfusions were done during the study period, in which PRBC’S were majorly transfused
136(65.38%) followed by Platelets 34 (16.3%). About 24 Transfusion reactions were reported in study
population, the PRBC’s 66.6% (16) contributed to the greater number of transfusion reactions in

comparison with Platelets 12.5% (03). The distribution of nature of adverse events showed Anaphylactic
reactions 06 (25%) with highest followed by DHTR 01 (4.1%) to be the lowest. About 12(50%)
transfusion reactions were of Grade 1, followed by 09(37.5%) transfusion reactions were of Grade 2, 03
(12.5%) transfusion reactions of Grade-3 & no reactions reported were of Grade4 severity respectively.
In order to manage the transfusion reaction highest cases were managed by Anti-histamines, Antipyretics,
Vasopressors followed by least caseswere managed by Antibiotics and Anti-emetic.
CONCLUSION: The active role of Clinical pharmacist in reporting transfusion reactions can help in
policy making by identifying trends. Evidence based recommendations can be generated from transfusion
reports leading to more informed decisions from the clinician’s end. Ensuring better outcomes for the
patients undergoing transfusions.

References

Shander A, Nemeth J, Cruz JE, Javidroozi M. Patient blood management: A role for pharmacists.

Am J Health Syst Pharm [Internet]. 2017;74(1): e83–9. Available from:

http://dx.doi.org/10.2146/ajhp151048

de Vries RRP, Faber J-C, Strengers PFW, Board of the International Hemovigilance Network.

Hemovigilance: an effective tool for improving transfusion practice: Hemovigilance. Vox Sang

[Internet]. 2011;100(1):60–7. Available from: http://dx.doi.org/10.1111/j.1423-

2010.01442.x

World Health Organization. A guide to establishing a national hemovigilance system. Genève,

Switzerland: World Health Organization; 2017

Boparai JK, Singh S. Hemovigilance: A new beginning in India. Int J Appl Basic Med Res

[Internet]. 2015;5(3):200–2. Available from: http://dx.doi.org/10.4103/2229-516X.165379

Sreekumar PK. Hemovigilance in India - A Milestone in Transfusion Safety.

Mukherjee S, Maiti R. Hemovigilance: A current update in Indian perspective. J ClinDiagn Res

[Internet]. 2016;10(11):EE05–9. Available from:

http://dx.doi.org/10.7860/JCDR/2016/21029.8868

International journal of pharmaceutical sciences and research. Vol. 11. International Journal of

Pharmaceutical Sciences and Research; 2020.

Sukanta Sen1*, Dr. Pankaj Gupta 2 , Dr. Satwika Sinha 3 , Dr. PawanBhambani. Hemovigilance and

Transfusion Safety: A Review. Scholars Journal of Applied Medical Sciences (SJAMS).

;2(1A):85–90

. https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability

. https://www.ncbi.nlm.nih.gov/books/NBK138219/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868404/#:~:text=Premedication%20with%20ac

etaminophen%20and%20diphenhydramine,in%20the%20US%20and%20Canada

Dr. Prasanna, Ganpisetti DRR, Susmitha DRG. To track adverse reactions, events and incidence

associated with blood and blood product transfusion: Pharmaceutical science-medicine. Int J Life

Sci Pharma Res [Internet]. 2019;9(3). Available from:

http://dx.doi.org/10.22376/ijpbs/lpr.2019.9.3.p48-60

Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, et al. Duration of red-cell

storage and complications after cardiac surgery. N Engl J Med [Internet]. 2008;358(12):1229–39.

Available from: http://dx.doi.org/10.1056/NEJMoa070403

Downloads

Published

2023-03-25

Issue

Vol. 9 No. 3 (2022)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.